Tax loss selling for 2021 just beginning and mean while Anavex is going back to basic research trying to figure out a new plan for the next decade of dilution.
How is that for a bit of upper echelon bio checking?
The situation that is holding the share price down hasn't changes in any material way.
The MOA is still unproven in many peoples eyes. The paradigm is still novel and unaccepted by the general biotech investor. The company doesn't have an approved drug, has not applied for an NDA yet. And the relatively low volume does make the share price vulnerable to manipulation by the usual market forces. The only completed placebo controlled trial has not yet released a full report for detailed analysis.
News 
Market Data 
Discover 
